Lomitapide

Lomitapide
Clinical data
Trade names	Juxtapid (US), Lojuxta (EU)
Other names	AEGR-773, BMS-201038
License data	EU EMA: by INN; US DailyMed: Lomitapide; US FDA: Lomitapide;
Routes of; administration	By mouth
ATC code	C10AX12 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluoren-9-carboxamide;
CAS Number	182431-12-5 ; mesylate: 202914-84-9;
PubChem CID	9853053; mesylate: 11274333;
IUPHAR/BPS	7439;
DrugBank	DB08827 ; mesylate: DBSALT000110;
ChemSpider	8028764 ; mesylate: 9449335;
UNII	82KUB0583F; mesylate: X4S83CP54E;
KEGG	D09637 ; mesylate: D09638;
ChEBI	CHEBI:72297 ; mesylate: CHEBI:72299;
ChEMBL	ChEMBL354541; mesylate: ChEMBL2105662;
CompTox Dashboard (EPA)	DTXSID50171294 ;
Chemical and physical data
Formula	C39H37F6N3O2
Molar mass	693.734 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c5ccc(cc5)-c1ccccc1C(=O)NC4CCN(CC4)CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c6ccccc26;
	InChI InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49) ; Key:MBBCVAKAJPKAKM-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lomitapide , sold under the brand name Juxtapid in the US and Lojuxta in the EU, is a medication used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals. It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.

The US Food and Drug Administration (FDA) approved lomitapide in December 2012, as an orphan drug to reduce LDL cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in people with homozygous familial hypercholesterolemia (HoFH).

In July 2013, the European Commission approved lomitapide as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adults with HoFH.